Journal Home
Search for

Volume 16, Issue 6, Pages 609-616 (June 2009)


View previous. 17 of 27 View next.

Comparative research of chemical constituents, antifungal and antitumor properties of ether extracts of Panax ginseng and its endophytic fungus

Li-Li Xua1, Ting Hana1, Jin-Zhong Wub, Qiao-Yan Zhanga, Hong Zhanga, Bao-Kang Huanga, Khalid Rahmanc, Lu-Ping QinaCorresponding Author Informationemail address

Abstract 

The chemical compositions and bioactivities of ether extracts of an endophytic fungus Paecilomyces sp. isolated from Panax ginseng were reported, and the comparative analysis of the constituents, antifungal and antitumor properties of the ether extracts from this fungus and its host ginseng were also conducted. By means of GC/MS technique, 51 compounds of Panax ginseng and 38 compounds of Paecilomyce sp. were determined. It is attractive that the extracts derived from Paecilomyce sp. and ginseng samples contained the same compound falcarinol, a natural pesticide and anti-cancer agent. The ether extracts of Paecilomyce sp., tested at 7.8μg/ml, completely inhibited the visible growth of Pyricularia oryzae. Furthermore, both extracts were tested against four human pathogenic fungi and showed the IC80 of Paecilomyce sp. was 4μg/ml against Trichophyton rubrum, equally to the control. Finally, the in vitro antitumor experience showed that the most of the IC50 values were all being below 20μg/ml.

a School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China

b Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350003, PR China

c Faculty of Science, School of Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK

Corresponding Author InformationCorresponding author. Tel./fax: +862125070394.

1 These authors equally contributed to this manuscript; both should be considered as first author.

PII: S0944-7113(09)00082-8

doi:10.1016/j.phymed.2009.03.014


View previous. 17 of 27 View next.